Article
Oncology
Donghao Xu, Yu Liu, Wentao Tang, Lingsha Xu, Tianyu Liu, Yudong Jiang, Shizhao Zhou, Xiaorui Qin, Jisheng Li, Jiemin Zhao, Lechi Ye, Wenju Chang, Jianmin Xu
Summary: This study examined the treatment patterns of regorafenib in patients with advanced metastatic colorectal cancer in China. The results showed that both regorafenib monotherapy and combination therapy provided some relief for patients, with regorafenib plus anti-PD-1 antibodies showing better progression-free survival and regorafenib plus chemotherapy yielding the greatest benefit in overall survival. The study also found no significant difference in adverse events among the three groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
E. Eraslan, M. Dogan, F. Yildiz, A. Ilhan, O. B. Oksuzoglu
Summary: In patients with metastatic colorectal cancer who failed on regorafenib treatment, rechallenge chemotherapy demonstrated a significant survival benefit compared to best supportive care, particularly in patients with a better Eastern Cooperative Oncology Group Performance Status (ECOG PS).
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Oncology
Anuj K. Patel, Ritika Abhyankar, Lauren K. Brais, Mei Sheng Duh, Victoria E. Barghout, Lynn Huynh, Mihran A. Yenikomshian, Kimmie Ng, Charles S. Fuchs
Summary: Patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil (FTD/TPI) are more likely to have better tumor response and disease control compared to those treated with regorafenib. Subgroup analysis suggests that early use of FTD/TPI may have clinical benefits.
Article
Oncology
Emaan Haque, Ibrahim N. Muhsen, Abdullah Esmail, Godsfavour Umoru, Charisma Mylavarapu, Veronica B. Ajewole, Maen Abdelrahim
Summary: This study retrospectively reviewed the data of metastatic colorectal cancer patients who received combination therapy of regorafenib and fluorouracil. The results showed that this treatment option could provide disease control for some patients without new adverse events.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
Summary: The study found that regorafenib treatment can cause hypertension and identified the risk factors associated with severe hypertension. Pre-existing primary hypertension and previous anti-VEGF treatment for >= 700 days were found to be independent risk factors for the development of hypertension.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Gastroenterology & Hepatology
Wattana Leowattana, Pathomthep Leowattana, Tawithep Leowattana
Summary: Significant progress has been made in the treatment of metastatic colorectal cancer (mCRC) over the past 20 years. Various treatment options are available for first-line treatment of mCRC. Advanced molecular technologies have identified new prognostic and predictive biomarkers for CRC. The development of next-generation sequencing and whole-exome sequencing has greatly advanced DNA sequencing technology and facilitated customized treatment delivery.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Van K. Morris, Erin B. Kennedy, Nancy N. Baxter, Al B. Benson, Andrea Cercek, May Cho, Kristen K. Ciombor, Chiara Cremolini, Anjee Davis, Dustin A. Deming, Marwan G. Fakih, Sepideh Gholami, Theodore S. Hong, Ishmael Jaiyesimi, Kelsey Klute, Christopher Lieu, Hanna Sanoff, John H. Strickler, Sarah White, Jason A. Willis, Cathy Eng
Summary: The purpose of this study is to develop treatment recommendations for patients with metastatic colorectal cancer (mCRC). An Expert Panel convened by ASCO conducted a systematic review of relevant studies and developed recommendations for clinical practice. Based on the inclusion criteria, five systematic reviews and ten randomized controlled trials were included in the analysis. The recommendations include offering doublet chemotherapy or triplet therapy to previously untreated mCRC patients who are initially unresectable, based on studies of chemotherapy combined with anti-vascular endothelial growth factor antibodies. Pembrolizumab is recommended for first-line treatment of mCRC patients with microsatellite instability-high or deficient mismatch repair tumors. Chemotherapy and anti-epidermal growth factor receptor therapy are recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC, while chemotherapy and anti-vascular endothelial growth factor therapy are recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for previously treated BRAF V600E-mutant mCRC patients who have progressed after one previous line of therapy. Other recommendations are provided for patients with colorectal peritoneal metastases, liver metastases, and candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are also recommended.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Hong Zhou, Yuehui Wang, Yanfang Lin, Wenjie Cai, Xiaofeng Li, Xiaomeng He
Summary: This study investigated the efficacy and safety of camrelizumab when added to XELOX chemotherapy plus bevacizumab or regorafenib as first-line therapy for mCRC. Results showed that this combination therapy was feasible and produced a high response rate of 72% in Chinese patients with MSS mCRC, with generally tolerable and manageable toxicities.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Keigo Chida, Daisuke Kotani, Yoshiaki Nakamura, Akihito Kawazoe, Yasutoshi Kuboki, Kohei Shitara, Takashi Kojima, Hiroya Taniguchi, Jun Watanabe, Itaru Endo, Takayuki Yoshino
Summary: The study demonstrated that patients treated with TAS102 plus BEV had longer overall survival and progression-free survival compared to those treated with TAS102 or regorafenib monotherapy. TAS102 plus BEV was independently associated with better OS and PFS on multivariate analysis, with no unexpected adverse events observed in any group.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2021)
Review
Oncology
Sara Cherri, Ester Oneda, Laura Zanotti, Alberto Zaniboni
Summary: Colorectal cancer is a significant health problem due to its incidence and biological complexity. Distinguishing different types of colorectal cancer based on specific characteristics is crucial for better therapeutic outcomes. The future challenge lies in studying effective combination treatments to overcome resistance mechanisms and achieve long-term treatment success. It is also important to prioritize the best therapies for first-line treatment and refine patient selection.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Shunsuke Hamasaki, Yosuke Fukunaga, Satoshi Nagayama, Yoshiya Fujimoto, Takashi Akiyoshi, Toshiya Nagasaki, Masashi Ueno
Summary: This study evaluated the clinicopathological characteristics of ovarian metastases from colorectal cancer and the impact of metastatic resection. It found that R0 resection resulted in better prognosis and poor prognosis was associated with peritoneal dissemination and extra-ovarian metastases. The study also suggested that resuming chemotherapy without changing the regimen after resection could preserve future treatment options and improve prognosis.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Masayuki Nakashima, Masato Takeuchi, Shiro Tanaka, Koji Kawakami
Summary: This study showed that chemotherapy after regorafenib or TFTD was associated with prolonged overall survival in advanced CRC patients. Further research is needed to determine the appropriate treatment choice for these patients.
ANTICANCER RESEARCH
(2021)
Article
Oncology
Dae-Won Lee, Yoojoo Lim, Hwang-Phill Kim, Su Yeon Kim, Hanseong Roh, Jun-Kyu Kang, Kyung-Hun Lee, Min Jung Kim, Seung-Bum Ryoo, Ji Won Park, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Sae-Won Han, Tae-You Kim
Summary: This study investigated the dynamics of ctDNA in metastatic colorectal cancer patients treated with regorafenib. Higher baseline cfDNA concentration was associated with worse survival. After 2 cycles of treatment, majority of ctDNA mutations showed decreased VAF and were associated with longer progression-free survival. Reduction in ctDNA burden, as estimated by the sum of VAF, could predict treatment outcomes.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Multidisciplinary Sciences
Gulcan Bulut, Merve Guner Oytun, Elvina Almuradova, Mustafa Harman, Ruchan Uslu, Bulent Karabulut
Summary: This study revealed that achieving complete response in patients with unresectable metastatic colorectal cancer has a positive impact on both overall survival and progression-free survival. Patients who attained complete response generally had better prognosis, especially in those who underwent primary tumor resection.
Article
Biochemistry & Molecular Biology
Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos, Michalis Karamouzis
Summary: This retrospective study examined the clinical characteristics and efficacy of FTD/TPI in patients with metastatic colorectal cancer. The results showed that FTD/TPI is effective as a third-line treatment, regardless of mutational status and tumor sidedness, by prolonging progression-free survival and overall survival.